Literature DB >> 24331183

Stem cell-directed therapies in pancreatic cancer.

Rachit Kumar, Avani Dholakia, Zeshaan Rasheed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24331183      PMCID： PMC3868009          DOI： 10.1016/j.currproblcancer.2013.10.005

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  57 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells.

Authors:  Ubaldo E Martinez-Outschoorn; Richard G Pestell; Anthony Howell; Mark L Tykocinski; Fnu Nagajyothi; Fabiana S Machado; Herbert B Tanowitz; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

Review 3.  Notch: a key regulator of tumor angiogenesis and metastasis.

Authors:  Alejandro Garcia; Jessica J Kandel
Journal:  Histol Histopathol       Date:  2012-02       Impact factor: 2.303

4.  c-Met is a marker of pancreatic cancer stem cells and therapeutic target.

Authors:  Chenwei Li; Jing-Jiang Wu; Mark Hynes; Joseph Dosch; Bedabrata Sarkar; Theodore H Welling; Marina Pasca di Magliano; Diane M Simeone
Journal:  Gastroenterology       Date:  2011-08-22       Impact factor: 22.682

5.  Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.

Authors:  Andrew J Gentles; Sylvia K Plevritis; Ravindra Majeti; Ash A Alizadeh
Journal:  JAMA       Date:  2010-12-22       Impact factor: 56.272

6.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Authors:  Daniel D Von Hoff; Ramesh K Ramanathan; Mitesh J Borad; Daniel A Laheru; Lon S Smith; Tina E Wood; Ronald L Korn; Neil Desai; Vuong Trieu; Jose L Iglesias; Hui Zhang; Patrick Soon-Shiong; Tao Shi; N V Rajeshkumar; Anirban Maitra; Manuel Hidalgo
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

7.  Stem cell gene expression programs influence clinical outcome in human leukemia.

Authors:  Kolja Eppert; Katsuto Takenaka; Eric R Lechman; Levi Waldron; Björn Nilsson; Peter van Galen; Klaus H Metzeler; Armando Poeppl; Vicki Ling; Joseph Beyene; Angelo J Canty; Jayne S Danska; Stefan K Bohlander; Christian Buske; Mark D Minden; Todd R Golub; Igor Jurisica; Benjamin L Ebert; John E Dick
Journal:  Nat Med       Date:  2011-08-28       Impact factor: 53.440

8.  A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Authors:  N V Rajeshkumar; Zeshaan A Rasheed; Elena García-García; Fernando López-Ríos; Kosaku Fujiwara; William H Matsui; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-07-26       Impact factor: 6.261

9.  Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

Authors:  Zeshaan A Rasheed; Jie Yang; Qiuju Wang; Jeanne Kowalski; Irwin Freed; Christopher Murter; Seung-Mo Hong; Jan-Bart Koorstra; N V Rajeshkumar; Xiaobing He; Michael Goggins; Christine Iacobuzio-Donahue; David M Berman; Daniel Laheru; Antonio Jimeno; Manuel Hidalgo; Anirban Maitra; William Matsui
Journal:  J Natl Cancer Inst       Date:  2010-02-17       Impact factor: 13.506

10.  Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.

Authors:  Enza Lonardo; Patrick C Hermann; Maria-Theresa Mueller; Stephan Huber; Anamaria Balic; Irene Miranda-Lorenzo; Sladjana Zagorac; Sonia Alcala; Iker Rodriguez-Arabaolaza; Juan Carlos Ramirez; Raul Torres-Ruíz; Elena Garcia; Manuel Hidalgo; David Álvaro Cebrián; Rainer Heuchel; Matthias Löhr; Frank Berger; Peter Bartenstein; Alexandra Aicher; Christopher Heeschen
Journal:  Cell Stem Cell       Date:  2011-11-04       Impact factor: 24.633
View more
  2 in total

1.  Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine.

Authors:  Mao Lin; Yuan-Ying Yuan; Shu-Peng Liu; Juan-Juan Shi; Xin-An Long; Li-Zhi Niu; Ji-Bing Chen; Qiao Li; Ke-Cheng Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-10       Impact factor: 4.553

2.  Thalidomide inhibits proliferation and epithelial-mesenchymal transition by modulating CD133 expression in pancreatic cancer cells.

Authors:  Congying Chen; Ge Yu; Wenqin Xiao; Miao Xing; Jianbo Ni; Rong Wan; Guoyong Hu
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.